Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.60 |
| ▸ | BCHE | P06276 | 6/20 | 0.51 |
| ▸ | BACE1 | P56817 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11206512 | 1.00 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL31444680 | 1.00 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL1337308 | 1.00 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL6941799 | 1.00 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL13887811 | 1.00 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL3312916 | 0.87 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL566826 | 0.87 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL22755783 | 0.87 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL566825 | 0.87 | ACHE (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL3141958 | 0.86 | GAA (0.49) | ACHEBCHEBACE1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| EP-0092391-A2 | Novel piperidine derivatives and pharmaceutical compositions containing same | KYOWA HAKKO KOGYO CO., LTD (JP) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | ACHE 3357/4885BCHE 1985/4885BACE1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.